Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.

被引：7
|
作者：
Antoniotti, Carlotta
Cremolini, Chiara
Loupakis, Fotios
Bergamo, Francesca
Grande, Roberta
Tonini, Giuseppe
Garattini, Silvio Ken
Masi, Gianluca
Battaglin, Francesca
Lucchesi, Sara
Salvatore, Lisa
Corsi, Domenico C.
Di Fabio, Francesca
Banzi, Maria
Sensi, Elisa
Tomcikova, Daniela
Fontanini, Gabriell
Zagonel, Vittorina
Boni, Luca
Falcone, Alfredo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3543
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO
    Sunakawa, Y.
    Shiozawa, M.
    Watanabe, T.
    Ota, H.
    Yasui, H.
    Kochi, M.
    Manaka, D.
    Ohori, H.
    Yamaguchi, T.
    Kyogoku, T.
    Sagawa, T.
    Kubota, Y.
    Masuishi, T.
    Kotaka, M.
    Sekikawa, T.
    Shimada, K.
    Nakamura, M.
    Takeuchi, M.
    Ichikawa, W.
    Fujii, M.
    Tsuji, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S172 - S172
  • [22] The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
    Tsuji, Akihito
    Ohori, Hisatsugu
    Yamaguchi, Tatsuro
    Matsuura, Masato
    Nishioka, Atsujiro
    Makiyama, Akitaka
    Noura, Shingo
    Kochi, Mitsugu
    Sagawa, Tamotsu
    Kotaka, Masahito
    Kubota, Yutaro
    Sunakawa, Yu
    Sekikawa, Takashi
    Nakamura, Masato
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [24] Early tumor shrinkage (ETS) as clinical factor to select maintenance with cetuximab (cet) monotherapy in patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A secondary endpoint analysis of the ERMES study
    Orlandi, Armando
    Pinto, Carmine
    Calegari, Maria Alessandra
    Normanno, Nicola
    Maiello, Evaristo
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, M. Giulia
    Bergamo, Francesca
    Tonini, Giuseppe
    Tamberi, Stefano
    Avallone, Antonio
    Latiano, Tiziana Pia
    Rosati, Gerardo
    Pazzola, Antonio
    Ballestrero, Alberto
    Zaniboni, Alberto
    Formica, Vincenzo
    Barone, Carlo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER.
    Tsuji, Akihito
    Sunakawa, Yu
    Ichikawa, Wataru
    Kubota, Yutaro
    Kochi, Mitsugu
    Sekikawa, Takashi
    Sagawa, Tamotsu
    Kotaka, Masahito
    Nakamura, Masato
    Shimada, Ken
    Masuishi, Toshiki
    Satake, Hironaga
    Yabuno, Taichi
    Yoshida, Taichi
    Goto, Masahiro
    Ota, Hirofumi
    Okita, Yoshihiro
    Takeuchi, Masahiro
    Fujii, Masashi
    Nakajima, Toshifusa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [26] Positive hyperselection of sensitizing genomic alterations (GAs) in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) from the phase III study of first-line FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone (ERMES)
    Normanno, N.
    Rachiglio, A. M.
    Abate, R. Esposito
    Orlandi, A.
    Maiello, E.
    Maglietta, G.
    Damato, A.
    Maiello, M. R.
    Carotenuto, M.
    Calegari, M. A.
    Antonuzzo, L.
    Bordonaro, R.
    Zampino, M. G.
    Tamberi, S.
    Lonardi, S.
    Avallone, A.
    Latiano, T. P.
    Tamburini, E.
    Barone, C. A.
    Pinto, C.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S52 - S52
  • [27] Final results of the randomized phase II VOLFI trial (AIO-KRK0109): mFOLFOXIRI plus Panitumumab versus FOLFOXIRI as first line treatment in patients with RAS wild -type metastatic colorectal cancer (mCRC)
    Geissler, M.
    Tannapfel, A.
    Reinacher-Schick, A.
    Martens, U.
    Ricke, J.
    Riera-Knorrenschield, J.
    Kanzler, S.
    Held, S.
    Heinemann, V.
    Seufferlein, T.
    Modest, D.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [28] Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of patients with RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) (ERMES study)
    Normanno, Nicola
    Orlandi, Armando
    Maiello, Evaristo
    Rachiglio, Anna Maria
    Maglietta, Giuseppe
    Damato, Angela
    Calegari, Maria Alessandra
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria Giulia
    Tamberi, Stefano
    Lonardi, Sara
    Tonini, Giuseppe
    Rosati, Gerardo
    Latiano, Tiziana Pia
    Tamburini, Emiliano
    Maiello, Monica Rosaria
    Carotenuto, Marianeve
    Barone, Carlo
    Pinto, Carmine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.
    Cremolini, Chiara
    Loupakis, Fotios
    Masi, Gianluca
    Zagonel, Vittorina
    Bergamo, Francesca
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Pinta, Francesco
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Sonaglio, Claudia
    De Stefano, Alfonso
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [30] Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13)
    Watanabe, Takanori
    Tsuji, Akihito
    Shiozawa, Manabu
    Ota, Hirofumi
    Satake, Hironaga
    Yabuno, Taichi
    Hasegawa, Junichi
    Kochi, Mitsugu
    Manaka, Dai
    Sagawa, Tamotsu
    Kotaka, Masahito
    Kubota, Yutaro
    Sunakawa, Yu
    Sekikawa, Takashi
    Nakamura, Masato
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345